Umeclidinium and vilanterol

(Anoro Ellipta®)

Anoro Ellipta®

Drug updated on 11/10/2023

Dosage FormInhalation (oral; 62.5 mcg umeclidinium and 25 mcg vilanterol)
Drug ClassAnticholinergics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Product Monograph / Prescribing Information

Document TitleYearSource
Anoro Ellipta (umeclidinium and vilanterol) Prescribing Information.2023GlaxoSmithKline, Research Triangle Park, NC

Systematic Reviews / Meta-Analyses

Document TitleYearSource
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.2023European Journal of Clinical Pharmacology
Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. 2022Therapeutic Advances in Respiratory Disease
Efficacy and safety of LAMA/LABA fixed-dose combination therapies in chronic obstructive pulmonary disease: a systematic review of direct and indirect treatment comparisons.2022International Journal of Chronic Obstructive Pulmonary Disease
The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease.2022Canadian Respiratory Journal
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.2022Advances in Therapy
Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.2020Respiratory Research
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations.2019Pulmonary Pharmacology and Therapeutics
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.2019Cochrane Database of Systematic Reviews
Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: a systematic review.2019The Clinical Respiratory Journal
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.2019Pulmonary Pharmacology & Therapeutics
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.2019Pulmonary Pharmacology & Therapeutics
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.2019Respiratory research

Clinical Practice Guidelines